ASKA Pharmaceutical Holdings Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter resulted in decreases in both revenue and earnings, with the key takeaway being the substantial contraction in operating income and net income despite only a modest decline in revenue. Revenue was ¥173.8B (¥176.4B in the previous year, YoY -1.5%), operating income was ¥7.1B (¥14.6B in the previous year, YoY -51.4%), and ordinary income was ¥8.2B (¥15.9B in the previous year, YoY -48.7%). Net income attributable to owners of the parent was ¥5.3B (¥12.6B in the previous year, YoY -57.5%). The absence in the current period of the one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year also amplified the earnings decline. The primary factors were a decline in overseas business revenue (-25.9%), a lower gross margin due to an unfavorable business mix (46.5%, down 240bp year on year), and negative operating leverage resulting from higher SG&A expenses (+3.0%).

Factors Affecting Business Performance

【Revenue】Revenue was ¥173.8B, down -1.5% year on year. The Pharmaceutical Business, which accounts for 83.3% of the revenue mix, was nearly flat at ¥144.8B (-0.2%). While the Animal Health Business grew to ¥19.5B (+6.0%), the Overseas Business declined substantially to ¥9.1B (-25.9%), becoming the primary factor behind the deterioration in the top line.

【Profit and Loss】Operating income was ¥7.1B (-51.4%). The gross margin declined by -240bp to 46.5% (48.9% in the previous year), while SG&A expenses increased to ¥73.8B (+3.0%) and the SG&A ratio rose to 42.4% (+180bp), resulting in negative operating leverage. By segment, operating income in the Pharmaceutical Business contracted to ¥11.3B (-33.3%), while the Overseas Business fell into a loss of ¥-0.3B. Ordinary income was ¥8.2B (-48.7%), with higher interest expenses (¥0.9B versus ¥0.5B in the previous year) and equity-method investment losses (¥0.6B) acting as downward factors. Net income attributable to owners of the parent was ¥5.3B (-57.5%), with the absence in the current period of the one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year also amplifying the earnings decline. Both revenue and earnings decreased.

Segment Analysis

The Pharmaceutical Business generated revenue of ¥144.8B (83.3% of revenue, YoY -0.2%) and operating income of ¥11.3B (YoY -33.3%, margin 7.8%). Although it remains the primary earnings contributor, its margin declined significantly from the previous year. The Animal Health Business was the only segment to achieve revenue growth, with revenue of ¥19.5B (YoY +6.0%), but operating income was limited to ¥0.4B (YoY -65.6%, margin 2.3%), indicating that the revenue increase did not translate into higher earnings. The Overseas Business recorded revenue of ¥9.1B (YoY -25.9%) and operating income of ¥-0.3B (margin -3.9%), falling into the red and becoming a factor weighing on the group-wide margin. The Other segment was small, with revenue of ¥0.5B and an operating loss of ¥0.1B. The fact that even the revenue-growing segment did not achieve earnings growth highlights the need to review the cost structure.

Key Financial Indicators

【Profitability】The operating margin declined substantially to 4.1% (8.3% in the previous year), while the net margin fell to 3.1% (7.1% in the previous year). ROE was 0.7%, primarily due to the contraction in net income attributable to owners of the parent. 【Cash Flow Quality】Comprehensive income was ¥14.1B, exceeding net income of ¥5.3B; however, the difference was attributable to other comprehensive income, including a +¥8.0B valuation difference on securities and a +¥1.4B foreign currency translation adjustment, and does not indicate an improvement in cash-generation capacity. 【Investment Efficiency】Total asset turnover was low at 0.158x (quarterly), with inventories of ¥150.7B and accounts receivable of ¥165.9B weighing on asset efficiency. Goodwill was ¥23.4B, equivalent to 3.0% of net assets, indicating limited dependence on M&A. 【Financial Soundness】The equity ratio was 64.4% (62.6% in the previous year), and the current ratio was 289.2%, both high levels indicating sound short-term payment capacity. Interest-bearing debt (total short- and long-term borrowings) was ¥118.4B, while immediate coverage from cash and deposits of ¥71.1B (down -29.8% year on year) had declined from the previous year.

Cash Flow Analysis

As no statement of cash flows was disclosed, trends in funding are assessed based on changes in the balance sheet. Cash and deposits declined -29.8% to ¥71.1B from ¥101.3B in the same period of the previous year. Meanwhile, short-term borrowings increased to ¥41.6B (¥32.7B in the previous year, +27.3%), indicating a change in the funding mix. Inventories increased to ¥150.7B (¥147.4B in the previous year, +2.2%), and trade receivables increased to ¥165.9B (¥160.2B in the previous year, +3.5%), while accounts payable declined to ¥47.5B (¥52.9B in the previous year, -10.2%). The increase in working capital appears to have tied up funds. This accumulation of working capital is considered one factor behind the decline in cash and increase in short-term borrowings, making improvements in inventory management and the collection cycle for trade receivables key to future funding efficiency.

Earnings Quality

Current-period profit before tax of ¥8.2B was equal to ordinary income of ¥8.2B, and no extraordinary gains or losses were recorded. In the same period of the previous year, however, profit before tax was ¥16.9B versus ordinary income of ¥15.9B, reflecting the recognition of a ¥0.96B extraordinary gain from the sale of fixed assets. The disappearance of this temporary boost in the current period should be noted when making YoY comparisons. Non-operating income was ¥3.0B, primarily consisting of the stable income source of ¥1.8B in dividend income. Non-operating expenses totaled ¥1.9B, including interest expenses of ¥0.9B, up from ¥0.5B in the previous year, which pressured income at the ordinary income level. Comprehensive income was ¥14.1B, exceeding net income attributable to owners of the parent of ¥5.3B; the primary factor was the unrealized valuation gain of +¥8.0B on securities, which does not indicate an improvement in underlying earnings power.

Earnings Forecasts and Guidance

Q1 progress against the full-year company plan was 23.8% for revenue (¥173.8B/¥730.0B), 11.5% for operating income (¥7.1B/¥62.0B), 13.4% for ordinary income (¥8.2B/¥61.0B), and 11.1% for net income attributable to owners of the parent (¥5.3B/¥48.0B). Revenue progress was nearly in line with a simple pro rata assumption of 25%, but progress on earnings was substantially lower. Achieving the full-year plan will therefore depend on improvements in the gross margin and cost efficiency in the second half. The company disclosed that there was “none” for both revisions to its earnings forecast and dividend forecast, and it is maintaining its full-year plan at this time.

Shareholder Returns

The company forecasts an annual dividend of ¥65 per share. Based on the period-average number of shares outstanding of 2,839.6万 shares, the total annual dividend is approximately ¥18.5B. The payout ratio against the full-year net income plan of ¥48.0B is approximately 38.5%, and no revision to the dividend forecast has been made despite the slow progress in earnings during Q1. No disclosure regarding share repurchases was made, and shareholder returns are assessed solely on the basis of dividends.

Risk Factors

1. Deterioration in the Overseas Business: Revenue in the Overseas Business was ¥9.1B (YoY -25.9%), while operating income was ¥-0.3B, falling from a profit into a loss. The unfavorable mix was a factor weighing on the group-wide gross margin (-240bp), and its impact on profitability may continue.

2. Accumulation of Working Capital and Declining Cash-Generation Capacity: While inventories of ¥150.7B and trade receivables of ¥165.9B accumulated, cash and deposits declined to ¥71.1B (-29.8%) and short-term borrowings increased to ¥41.6B (+27.3%). Delays in improving funding efficiency could lead to additional funding requirements.

3. Higher Interest Burden and Equity-Method Losses: Interest expenses increased to ¥0.9B (¥0.5B in the previous year), while equity-method investment losses of ¥0.6B also pressured ordinary income. Interest rate trends on interest-bearing debt of ¥118.4B may affect ordinary income going forward.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the operating margin and net margin are substantially below the industry median, placing the company in the lower tier of the industry in terms of profitability.

Growth and Capital Efficiency

The revenue growth rate is also substantially below the industry median, placing the company in the lower tier of the industry in terms of growth.

Source: Compiled by the Company

Key Points from the Earnings Report

1. Full-year progress rates were substantially below the simple pro rata benchmark of 25%, at 11.5% for operating income and 11.1% for net income. The degree to which earnings recovery can be achieved in the second half will be a key point to monitor in future earnings reports.

2. The one-time ¥0.96B gain on the sale of fixed assets recorded in the previous year did not recur in the current period. Accordingly, the composition from ordinary income through net income is closer to an underlying business-based result.

3. The fact that the revenue-growing Animal Health Business (+6.0%) did not achieve earnings growth, together with the Overseas Business falling into the red and weighing on the group-wide margin, are important points for assessing the earnings structure of the business portfolio.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,434–¥2,575 for a ±1% change in the cost of equity, and ¥2,495–¥2,508 for a ±0.1 change in ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used; there is a timing difference from the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---